{"id":168198,"date":"2024-01-04T02:38:07","date_gmt":"2024-01-04T07:38:07","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/starton-therapeutics-announces-initial-key-safety-and-efficacy-signals-with-star-lld-in-patients-with-relapsed-or-refractory-multiple-myeloma\/"},"modified":"2024-08-18T11:46:58","modified_gmt":"2024-08-18T15:46:58","slug":"starton-therapeutics-announces-initial-key-safety-and-efficacy-signals-with-star-lld-in-patients-with-relapsed-or-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/starton-therapeutics-announces-initial-key-safety-and-efficacy-signals-with-star-lld-in-patients-with-relapsed-or-refractory-multiple-myeloma.php","title":{"rendered":"Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma"},"content":{"rendered":"<p><![CDATA[PARAMUS, N.J., Jan.  03, 2024  (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (\u201cStarton\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, announced today initial key safety and efficacy signals of its STAR-LLD Phase 1b clinical trial in multiple myeloma.]]><\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/01\/03\/2803591\/0\/en\/Starton-Therapeutics-Announces-Initial-Key-Safety-and-Efficacy-Signals-with-STAR-LLD-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma\">Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Excerpt from: Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/starton-therapeutics-announces-initial-key-safety-and-efficacy-signals-with-star-lld-in-patients-with-relapsed-or-refractory-multiple-myeloma.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-168198","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/168198"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=168198"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/168198\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=168198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=168198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=168198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}